Instytut Msf Sp. z o.o.

At Instytut Msf Sp. z o.o. in Lodz, much of the clinical trial activity focuses on neoplasms, especially breast cancer, non-small cell lung cancer, and other advanced solid tumors. These studies are generally aimed at testing new cancer therapies, comparing them with current standards, and improving outcomes for patients with difficult-to-treat disease.

• Breast cancer, including hormone receptor-positive, HER2-negative, HER2-low, and triple-negative subtypes
• Non-small cell lung cancer across advanced, metastatic, and treatment-naive settings
• Advanced solid tumors and broader pan-tumor research
• Evaluation of new treatment options and comparison with established cancer care

Several studies also explore whether combining targeted and immunotherapy approaches can better control cancer growth and extend survival.

The site is active in research on breast cancer in both early and advanced stages, with special attention to hormone receptor-positive and HER2-negative disease. These trials often aim to refine treatment selection, reduce recurrence risk, and improve disease control in patients with metastatic or high-risk early disease.

• Hormone receptor-positive breast cancer in early and metastatic settings
• HER2-negative and HER2-low breast cancer
• Triple-negative breast cancer and locally recurrent disease
• Testing newer therapies and combinations against standard endocrine or chemotherapy-based care

Research at this site includes efforts to improve both progression-free survival and long-term outcomes for patients with recurrent or advanced breast cancer.

A major research focus is non-small cell lung cancer, including locally advanced, metastatic, and post-surgical disease, along with some studies in small-cell lung cancer. The trials are designed to evaluate new immunotherapy, targeted therapy, and combination approaches that may offer better disease control than existing options.

• Non-small cell lung cancer, including EGFR-mutated and EGFR/ALK wild-type disease
• Metastatic and locally advanced lung cancer
• Small-cell lung cancer in extensive-stage disease
• Assessing survival, recurrence prevention, and treatment effectiveness

These studies reflect a strong interest in finding more effective treatments for patients with advanced lung cancer, including those who have already received prior therapy.

Beyond breast and lung cancer, the site also contributes to studies in ovarian cancer, urothelial carcinoma, pancreatic cancer, colorectal cancer, and other recurrent or metastatic solid tumors. This work supports broader oncology research aimed at identifying new treatment options for patients with limited alternatives.

• Ovarian cancer, including disease that has progressed after prior treatment
• Urothelial carcinoma and other urinary tract cancers
• Pancreatic, colorectal, and other metastatic solid tumors
• Evaluating anti-tumor activity and comparing newer therapies with standard care

These trials often focus on patients with recurrent or metastatic disease, where new treatment approaches are especially needed.

In addition to cancer treatment studies, the site’s portfolio includes work in diagnostic and surgical procedures, along with selected research linked to female urogenital diseases and hematologic conditions. There is also some activity in psychiatry and psychology, reflecting a broader interest in patient care and clinical support.

• Analytical and diagnostic research
• Surgical procedures and operative care-related studies
• Female urogenital diseases and pregnancy-related complications
• Hemic and lymphatic diseases plus selected behavioral and psychological research

This mix shows that Instytut Msf Sp. z o.o. supports both advanced oncology trials and additional clinical research areas that may improve diagnosis, treatment planning, and patient care.